MersV1, PubMed, Corpus, bibRecord, 000058

Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.

Identifieur interne : 000058 ( PubMed/Corpus ); précédent : 000057; suivant : 000059

Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.

Auteurs : Tiffany Tang ; Miya Bidon ; Javier A. Jaimes ; Gary R. Whittaker ; Susan Daniel

Source :

Antiviral research [ 1872-9096 ] ; 2020.

RBID : pubmed:32272173

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2, and also against other pathogenic coronaviruses (CoV) that have emerged in the past or might appear in future. Researchers are therefore focusing on steps in the CoV replication cycle that may be vulnerable to inhibition by broad-spectrum or specific antiviral agents. The conserved nature of the fusion domain and mechanism across the CoV family make it a valuable target to elucidate and develop pan-CoV therapeutics. In this article, we review the role of the CoV spike protein in mediating fusion of the viral and host cell membranes, summarizing the results of research on SARS-CoV, MERS-CoV, and recent peer-reviewed studies of SARS-CoV-2, and suggest that the fusion mechanism be investigated as a potential antiviral target. We also provide a supplemental file containing background information on the biology, epidemiology, and clinical features of all human-infecting coronaviruses, along with a phylogenetic tree of these coronaviruses.

DOI: 10.1016/j.antiviral.2020.104792
PubMed: 32272173

Links to Exploration step

pubmed:32272173

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.</title>
<author><name sortKey="Tang, Tiffany" sort="Tang, Tiffany" uniqKey="Tang T" first="Tiffany" last="Tang">Tiffany Tang</name>
<affiliation><nlm:affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bidon, Miya" sort="Bidon, Miya" uniqKey="Bidon M" first="Miya" last="Bidon">Miya Bidon</name>
<affiliation><nlm:affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jaimes, Javier A" sort="Jaimes, Javier A" uniqKey="Jaimes J" first="Javier A" last="Jaimes">Javier A. Jaimes</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Cornell University, Ithaca, NY, 14853, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Whittaker, Gary R" sort="Whittaker, Gary R" uniqKey="Whittaker G" first="Gary R" last="Whittaker">Gary R. Whittaker</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Cornell University, Ithaca, NY, 14853, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Daniel, Susan" sort="Daniel, Susan" uniqKey="Daniel S" first="Susan" last="Daniel">Susan Daniel</name>
<affiliation><nlm:affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA. Electronic address: sd386@cornell.edu.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32272173</idno>
<idno type="pmid">32272173</idno>
<idno type="doi">10.1016/j.antiviral.2020.104792</idno>
<idno type="wicri:Area/PubMed/Corpus">000058</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000058</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.</title>
<author><name sortKey="Tang, Tiffany" sort="Tang, Tiffany" uniqKey="Tang T" first="Tiffany" last="Tang">Tiffany Tang</name>
<affiliation><nlm:affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bidon, Miya" sort="Bidon, Miya" uniqKey="Bidon M" first="Miya" last="Bidon">Miya Bidon</name>
<affiliation><nlm:affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Jaimes, Javier A" sort="Jaimes, Javier A" uniqKey="Jaimes J" first="Javier A" last="Jaimes">Javier A. Jaimes</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Cornell University, Ithaca, NY, 14853, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Whittaker, Gary R" sort="Whittaker, Gary R" uniqKey="Whittaker G" first="Gary R" last="Whittaker">Gary R. Whittaker</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, Cornell University, Ithaca, NY, 14853, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Daniel, Susan" sort="Daniel, Susan" uniqKey="Daniel S" first="Susan" last="Daniel">Susan Daniel</name>
<affiliation><nlm:affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA. Electronic address: sd386@cornell.edu.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="eISSN">1872-9096</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2, and also against other pathogenic coronaviruses (CoV) that have emerged in the past or might appear in future. Researchers are therefore focusing on steps in the CoV replication cycle that may be vulnerable to inhibition by broad-spectrum or specific antiviral agents. The conserved nature of the fusion domain and mechanism across the CoV family make it a valuable target to elucidate and develop pan-CoV therapeutics. In this article, we review the role of the CoV spike protein in mediating fusion of the viral and host cell membranes, summarizing the results of research on SARS-CoV, MERS-CoV, and recent peer-reviewed studies of SARS-CoV-2, and suggest that the fusion mechanism be investigated as a potential antiviral target. We also provide a supplemental file containing background information on the biology, epidemiology, and clinical features of all human-infecting coronaviruses, along with a phylogenetic tree of these coronaviruses.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32272173</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>06</Day>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.</ArticleTitle>
<Pagination><MedlinePgn>104792</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0166-3542(20)30206-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2020.104792</ELocationID>
<Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2, and also against other pathogenic coronaviruses (CoV) that have emerged in the past or might appear in future. Researchers are therefore focusing on steps in the CoV replication cycle that may be vulnerable to inhibition by broad-spectrum or specific antiviral agents. The conserved nature of the fusion domain and mechanism across the CoV family make it a valuable target to elucidate and develop pan-CoV therapeutics. In this article, we review the role of the CoV spike protein in mediating fusion of the viral and host cell membranes, summarizing the results of research on SARS-CoV, MERS-CoV, and recent peer-reviewed studies of SARS-CoV-2, and suggest that the fusion mechanism be investigated as a potential antiviral target. We also provide a supplemental file containing background information on the biology, epidemiology, and clinical features of all human-infecting coronaviruses, along with a phylogenetic tree of these coronaviruses.</AbstractText>
<CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName>
<ForeName>Tiffany</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bidon</LastName>
<ForeName>Miya</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jaimes</LastName>
<ForeName>Javier A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Cornell University, Ithaca, NY, 14853, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Whittaker</LastName>
<ForeName>Gary R</ForeName>
<Initials>GR</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Cornell University, Ithaca, NY, 14853, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Daniel</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, 14853, USA. Electronic address: sd386@cornell.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Middle East respiratory syndrome</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">Severe acute respiratory syndrome</Keyword>
<Keyword MajorTopicYN="N">Spike protein</Keyword>
<Keyword MajorTopicYN="N">fusion peptide</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32272173</ArticleId>
<ArticleId IdType="pii">S0166-3542(20)30206-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2020.104792</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000058 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000058 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32272173
   |texte=   Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:32272173" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.

Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki